+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Cardiac Biomarkers Market by Type, by Application, by Location of Testing - Global Opportunity Analysis and Industry Forecast, 2020 - 2030

  • PDF Icon

    Report

  • 296 Pages
  • September 2020
  • Region: Global
  • Next Move Strategy Consulting
  • ID: 5314555
Market Definition:

The Global Cardiac Biomarkers Market size was valued at USD 8.42 billion in 2019 and is predicted to reach USD 28.29 billion by 2030, with a CAGR of 11.6% from 2020-2030. Cardiac biomarkers are protein-based substrates released into the blood stream when the heart is extremely stressed or damaged. Cardiac biomarkers can be traced and measured to diagnose Cardio Vascular Diseases (CVDs) such as Acute Coronary Syndrome (ACS), myocardial infraction, cardiac ischemia, and others. Cardiac biomarker is an integrated diagnostic approach for prevention of CVDs by monitoring the heart conditions. Due to high sensitivity, it gives rapid results for immediately initiating the diagnostic and treatment procedures.

The adoption of cost-effective Cardiac Point of Care (PoC) testing kits that offer quick results with higher accuracy are gaining momentum over the period, thereby supplementing the growth of cardiac biomarkers market.

Market Dynamics and Trends:

According to the data by World Health Organization, more than 17.9 million people worldwide, die of Cardiovascular diseases (CVDs), every year. This scenario consequently escalates the demand for advanced healthcare facilities that offer precise diagnostics, monitoring and treatments options for patients suffering from CVDs, thereby propagating the growth of global cardiac biomarkers market.

Furthermore, benefits offered by cardiac biomarkers such as, fast and precise depictions of heart failures after the one-set of chest pain, and high sensitivity of biomarkers test-kit offering precise results; are expected to propagate the growth of global cardiac biomarkers market. However, limited use of biomarkers test in specific cases, and risk of skeletal injury are the limiting factors expected to slow down the growth of cardiac biomarkers market.

Moreover, multiple options to formulate different combinations for cardiac biomarkers testing, manufacturers offering various customized solutions, and increasing investment in the R&D activities for new clinical research by government and non-government authorities, are the factors anticipated to propel the growth of global cardiac biomarkers market in coming future.

Market Segmentations and Scope of the Study:

The global cardiac biomarkers market share has been analyzed based on type, application, location of testing and geography. Based on product type, the cardiac biomarkers market is segmented into myocardial muscle creatine kinase (CK-MB), myoglobin, brain natriuretic peptide (BNPs), troponins (T and I), or NT-proBNP, ischemia modified albumin (IMA), and others. Based on application, the market is categorized into myocardial infarction, congestive heart failure, acute coronary syndrome, atherosclerosis, and others. Based on location of testing, the market is divided into point of care testing and laboratory testing. Geographic breakdown and analysis of each of the previously mentioned segments include regions comprising North America, Europe, Asia-Pacific, and RoW.

Geographical Analysis:

North America dominated the global cardiac biomarkers market, and is expected to maintain this trend throughout the forecast period, accounting for the highest market share. This is attributed to well-established healthcare infrastructures and medical laboratories. Moreover, increasing incidences of CVDs due to sedimentary lifestyles, and adoption of PoC gaining momentum, are the factors expected to further propel the cardiac biomarkers market growth in this region.

Asia Pacific region is expected to grow substantially in the global cardiac biomarkers market, owing to increasing accessibility to healthcare facilities, higher prevalence of CVDs due constantly multiplying population, increasing medical tourism, and increasing awareness regarding treatment options.

Competitive Landscape:

The cardiac biomarkers market is highly competitive and consists of various market players. Some of the major market players include Roche Diagnostics, Siemens Healthcare, Abbott Laboratories, Alere Inc., Bio-Rad Laboratories, Becton, Dickinson and Company, BioMerieux, Beckman Coulter, Randox laboratories, and Thermo Fisher Scientific among others. An upsurge in R&D activities and new product launches by the key players, is leading the healthcare infrastructure to new heights, thereby creating lucrative opportunities in the global cardiac biomarkers market. For instance, in September 2019, Abbott, one of the major players in cardiac biomarkers market, introduced a test to assist in curing the troponin dilemma. Abbott’s High Sensitivity Troponin-I (hsTnI) blood test measures very low levels of troponin, allowing doctors to assess heart attack in patients within two to four hours of admission. It has achieved a green signal for commercialization in the U.S. to help diagnose heart attacks in men and women.

KEY MARKET SEGMENTS:

Global Cardiac Biomarkers market - By Type
  • Myocardial muscle Creatine Kinase (CK-MB)
  • Troponins (T and I)
  • Myoglobin
  • Brain Natriuretic Peptide (BNPs) or NT-proBNP
  • Ischemia Modified Albumin (IMA)
  • Others
Global Cardiac Biomarkers market - By Application
  • Myocardial Infarction
  • Congestive Heart Failure
  • Acute Coronary Syndrome
  • Atherosclerosis
  • Others
Global Cardiac Biomarkers market - By Point of Testing
  • Point of care testing
  • Laboratory testing
Global Cardiac Biomarkers market -By Geography
  • North America
  • U.S.
  • Canada
  • Mexico
  • Europe
  • UK
  • Germany
  • France
  • Italy
  • Rest of Europe
  • Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • Rest of Asia-Pacific
  • RoW
  • UAE
  • Saudi Arabia
  • South Africa
  • Brazil
  • Remaining countries

Table of Contents

1. Introduction
1.1. Report Description
1.2. Research Methodology
1.2.1 Secondary Research
1.2.2 Data Analysis Framework
1.2.3 Market Size Estimation
1.2.4 Forecasting
1.2.5 Primary Research and Data Validation
2. Market Snapshot, 2019-2030 Million USD
2.1. Market Snapshot
3. Porter's Five Force Model Analysis
4. Market Dynamics
4.1. Growth Drivers
4.1.1 Driver 1
4.1.2 Driver 2
4.1.3 Driver 3
4.1.4 Driver 4
4.2. Challenges
4.2.1 Challenge 1
4.2.2 Challenge 2
4.3. Opportunities
4.3.1 Opportunity 1
4.3.2 Opportunity 2
5. Global Cardiac Biomarkers Market, by Type
5.1. Overview
5.2. Creatine Kinase
5.2.1 Creatine Kinase Market, by Region
5.2.1.1 North America Creatine Kinase Market, by Country
5.2.1.2 Europe Creatine Kinase Market, by Country
5.2.1.3 Asia-Pacific Creatine Kinase Market, by Country
5.2.1.4 Rest of World Creatine Kinase Market, by Country
5.3. Troponins
5.3.1 Troponins Market, by Region
5.3.1.1 North America Troponins Market, by Country
5.3.1.2 Europe Troponins Market, by Country
5.3.1.3 Asia-Pacific Troponins Market, by Country
5.3.1.4 Rest of World Troponins Market, by Country
5.4. Myoglobin
5.4.1 Myoglobin Market, by Region
5.4.1.1 North America Myoglobin Market, by Country
5.4.1.2 Europe Myoglobin Market, by Country
5.4.1.3 Asia-Pacific Myoglobin Market, by Country
5.4.1.4 Rest of World Myoglobin Market, by Country
5.5. Natriuretic Peptides
5.5.1 Natriuretic Peptides Market, by Region
5.5.1.1 North America Natriuretic Peptides Market, by Country
5.5.1.2 Europe Natriuretic Peptides Market, by Country
5.5.1.3 Asia-Pacific Natriuretic Peptides Market, by Country
5.5.1.4 Rest of World Natriuretic Peptides Market, by Country
5.6. Ischemia Modified Albumin
5.6.1 Ischemia Modified Albumin Market, by Region
5.6.1.1 North America Ischemia Modified Albumin Market, by Country
5.6.1.2 Europe Ischemia Modified Albumin Market, by Country
5.6.1.3 Asia-Pacific Ischemia Modified Albumin Market, by Country
5.6.1.4 Rest of World Ischemia Modified Albumin Market, by Country
5.7. Other Type
5.7.1 Other Type Market, by Region
5.7.1.1 North America Other Type Market, by Country
5.7.1.2 Europe Other Type Market, by Country
5.7.1.3 Asia-Pacific Other Type Market, by Country
5.7.1.4 Rest of World Other Type Market, by Country
6. Global Cardiac Biomarkers Market, by Application
6.1. Overview
6.2. Myocardial Infarction
6.2.1 Myocardial Infarction Market, by Region
6.2.1.1 North America Myocardial Infarction Market, by Country
6.2.1.2 Europe Myocardial Infarction Market, by Country
6.2.1.3 Asia-Pacific Myocardial Infarction Market, by Country
6.2.1.4 Rest of World Myocardial Infarction Market, by Country
6.3. Congestive Heart Failure
6.3.1 Congestive Heart Failure Market, by Region
6.3.1.1 North America Congestive Heart Failure Market, by Country
6.3.1.2 Europe Congestive Heart Failure Market, by Country
6.3.1.3 Asia-Pacific Congestive Heart Failure Market, by Country
6.3.1.4 Rest of World Congestive Heart Failure Market, by Country
6.4. Acute Coronary Syndrome
6.4.1 Acute Coronary Syndrome Market, by Region
6.4.1.1 North America Acute Coronary Syndrome Market, by Country
6.4.1.2 Europe Acute Coronary Syndrome Market, by Country
6.4.1.3 Asia-Pacific Acute Coronary Syndrome Market, by Country
6.4.1.4 Rest of World Acute Coronary Syndrome Market, by Country
6.5. Atherosclerosis
6.5.1 Atherosclerosis Market, by Region
6.5.1.1 North America Atherosclerosis Market, by Country
6.5.1.2 Europe Atherosclerosis Market, by Country
6.5.1.3 Asia-Pacific Atherosclerosis Market, by Country
6.5.1.4 Rest of World Atherosclerosis Market, by Country
6.6. Other Application
6.6.1 Other Application Market, by Region
6.6.1.1 North America Other Application Market, by Country
6.6.1.2 Europe Other Application Market, by Country
6.6.1.3 Asia-Pacific Other Application Market, by Country
6.6.1.4 Rest of World Other Application Market, by Country
7. Global Cardiac Biomarkers Market, by Location of Testing
7.1. Overview
7.2. Point of Care Testing
7.2.1 Point of Care Testing Market, by Region
7.2.1.1 North America Point of Care Testing Market, by Country
7.2.1.2 Europe Point of Care Testing Market, by Country
7.2.1.3 Asia-Pacific Point of Care Testing Market, by Country
7.2.1.4 Rest of World Point of Care Testing Market, by Country
7.3. Laboratory Testing
7.3.1 Laboratory Testing Market, by Region
7.3.1.1 North America Laboratory Testing Market, by Country
7.3.1.2 Europe Laboratory Testing Market, by Country
7.3.1.3 Asia-Pacific Laboratory Testing Market, by Country
7.3.1.4 Rest of World Laboratory Testing Market, by Country
8. Global Cardiac Biomarkers Market, by Region
8.1. Overview
8.2. North America
8.2.1 North America Cardiac Biomarkers Market, by Type
8.2.2 North America Cardiac Biomarkers Market, by Application
8.2.3 North America Cardiac Biomarkers Market, by Location of Testing
8.2.4 North America Cardiac Biomarkers, Market by Country
8.2.4.1 U.S.
8.2.4.1.1 U.S. Cardiac Biomarkers Market, by Type
8.2.4.1.2 U.S. Cardiac Biomarkers Market, by Application
8.2.4.1.3 U.S. Cardiac Biomarkers Market, by Location of Testing
8.2.4.2 Canada
8.2.4.2.1 Canada Cardiac Biomarkers Market, by Type
8.2.4.2.2 Canada Cardiac Biomarkers Market, by Application
8.2.4.2.3 Canada Cardiac Biomarkers Market, by Location of Testing
8.2.4.3 Mexico
8.2.4.3.1 Mexico Cardiac Biomarkers Market, by Type
8.2.4.3.2 Mexico Cardiac Biomarkers Market, by Application
8.2.4.3.3 Mexico Cardiac Biomarkers Market, by Location of Testing
8.3. Europe
8.3.1 Europe Cardiac Biomarkers Market, by Type
8.3.2 Europe Cardiac Biomarkers Market, by Application
8.3.3 Europe Cardiac Biomarkers Market, by Location of Testing
8.3.4 Europe Cardiac Biomarkers, Market by Country
8.3.4.1 Germany
8.3.4.1.1 Germany Cardiac Biomarkers Market, by Type
8.3.4.1.2 Germany Cardiac Biomarkers Market, by Application
8.3.4.1.3 Germany Cardiac Biomarkers Market, by Location of Testing
8.3.4.2 UK
8.3.4.2.1 UK Cardiac Biomarkers Market, by Type
8.3.4.2.2 UK Cardiac Biomarkers Market, by Application
8.3.4.2.3 UK Cardiac Biomarkers Market, by Location of Testing
8.3.4.3 France
8.3.4.3.1 France Cardiac Biomarkers Market, by Type
8.3.4.3.2 France Cardiac Biomarkers Market, by Application
8.3.4.3.3 France Cardiac Biomarkers Market, by Location of Testing
8.3.4.4 Rest of Europe
8.3.4.4.1 Rest of Europe Cardiac Biomarkers Market, by Type
8.3.4.4.2 Rest of Europe Cardiac Biomarkers Market, by Application
8.3.4.4.3 Rest of Europe Cardiac Biomarkers Market, by Location of Testing
8.4. Asia-Pacific
8.4.1 Asia-Pacific Cardiac Biomarkers Market, by Type
8.4.2 Asia-Pacific Cardiac Biomarkers Market, by Application
8.4.3 Asia-Pacific Cardiac Biomarkers Market, by Location of Testing
8.4.4 Asia-Pacific Cardiac Biomarkers, Market by Country
8.4.4.1 Japan
8.4.4.1.1 Japan Cardiac Biomarkers Market, by Type
8.4.4.1.2 Japan Cardiac Biomarkers Market, by Application
8.4.4.1.3 Japan Cardiac Biomarkers Market, by Location of Testing
8.4.4.2 India
8.4.4.2.1 India Cardiac Biomarkers Market, by Type
8.4.4.2.2 India Cardiac Biomarkers Market, by Application
8.4.4.2.3 India Cardiac Biomarkers Market, by Location of Testing
8.4.4.3 China
8.4.4.3.1 China Cardiac Biomarkers Market, by Type
8.4.4.3.2 China Cardiac Biomarkers Market, by Application
8.4.4.3.3 China Cardiac Biomarkers Market, by Location of Testing
8.4.4.4 Australia
8.4.4.4.1 Australia Cardiac Biomarkers Market, by Type
8.4.4.4.2 Australia Cardiac Biomarkers Market, by Application
8.4.4.4.3 Australia Cardiac Biomarkers Market, by Location of Testing
8.4.4.5 Rest of Asia-Pacific
8.4.4.5.1 Rest of Asia-Pacific Cardiac Biomarkers Market, by Type
8.4.4.5.2 Rest of Asia-Pacific Cardiac Biomarkers Market, by Application
8.4.4.5.3 Rest of Asia-Pacific Cardiac Biomarkers Market, by Location of Testing
8.5. Rest of World
8.5.1 Rest of World Cardiac Biomarkers Market, by Type
8.5.2 Rest of World Cardiac Biomarkers Market, by Application
8.5.3 Rest of World Cardiac Biomarkers Market, by Location of Testing
8.5.4 Rest of World Cardiac Biomarkers, Market by Country
8.5.4.1 Latin America
8.5.4.1.1 Latin America Cardiac Biomarkers Market, by Type
8.5.4.1.2 Latin America Cardiac Biomarkers Market, by Application
8.5.4.1.3 Latin America Cardiac Biomarkers Market, by Location of Testing
8.5.4.2 Middle East
8.5.4.2.1 Middle East Cardiac Biomarkers Market, by Type
8.5.4.2.2 Middle East Cardiac Biomarkers Market, by Application
8.5.4.2.3 Middle East Cardiac Biomarkers Market, by Location of Testing
8.5.4.3 Africa
8.5.4.3.1 Africa Cardiac Biomarkers Market, by Type
8.5.4.3.2 Africa Cardiac Biomarkers Market, by Application
8.5.4.3.3 Africa Cardiac Biomarkers Market, by Location of Testing
9. Company Profiles
9.1. Abbott Laboratories
9.1.1 Company Overview
9.1.2 Company Snapshot
9.1.3 Operating Business Segments
9.1.4 Product Portfolio
9.1.5 Business Performance
9.1.6 Key Strategic Moves and Development
9.2. Alere Inc.
9.2.1 Company Overview
9.2.2 Company Snapshot
9.2.3 Operating Business Segments
9.2.4 Product Portfolio
9.2.5 Business Performance
9.2.6 Key Strategic Moves and Development
9.3. Siemens Healthcare
9.3.1 Company Overview
9.3.2 Company Snapshot
9.3.3 Operating Business Segments
9.3.4 Product Portfolio
9.3.5 Business Performance
9.3.6 Key Strategic Moves and Development
9.4. Roche Diagnostics Corporation
9.4.1 Company Overview
9.4.2 Company Snapshot
9.4.3 Operating Business Segments
9.4.4 Product Portfolio
9.4.5 Business Performance
9.4.6 Key Strategic Moves and Development
9.5. Beckman Coulter
9.5.1 Company Overview
9.5.2 Company Snapshot
9.5.3 Operating Business Segments
9.5.4 Product Portfolio
9.5.5 Business Performance
9.5.6 Key Strategic Moves and Development
9.6. Becton, Dickinson and Co.
9.6.1 Company Overview
9.6.2 Company Snapshot
9.6.3 Operating Business Segments
9.6.4 Product Portfolio
9.6.5 Business Performance
9.6.6 Key Strategic Moves and Development
9.7. Thermo Fisher Scientific
9.7.1 Company Overview
9.7.2 Company Snapshot
9.7.3 Operating Business Segments
9.7.4 Product Portfolio
9.7.5 Business Performance
9.7.6 Key Strategic Moves and Development
9.8. Biomerieux
9.8.1 Company Overview
9.8.2 Company Snapshot
9.8.3 Operating Business Segments
9.8.4 Product Portfolio
9.8.5 Business Performance
9.8.6 Key Strategic Moves and Development
9.9. Bio-Rad Laboratories
9.9.1 Company Overview
9.9.2 Company Snapshot
9.9.3 Operating Business Segments
9.9.4 Product Portfolio
9.9.5 Business Performance
9.9.6 Key Strategic Moves and Development
9.10. Randox Laboratories
9.10.1 Company Overview
9.10.2 Company Snapshot
9.10.3 Operating Business Segments
9.10.4 Product Portfolio
9.10.5 Business Performance
9.10.6 Key Strategic Moves and Development

Executive Summary

Cardiac Biomarkers: Global Market Size, Trends, Competitive, Historical & Forecast Analysis, 2020 - 2030. Benefits offered by cardiac biomarkers such as, fast and precise depictions of heart failures after the one-set of chest pain, and high sensitivity of biomarkers test-kit offering precise results are factors driving the cardiac biomarkers market growth.

Cardiac biomarkers are protein-based substrates released into the blood stream when the heart is extremely stressed or damaged. Cardiac biomarkers can be traced and measured to diagnose Cardio Vascular Diseases (CVDs) such as Acute Coronary Syndrome (ACS), myocardial infraction, cardiac ischemia, and others. Cardiac biomarker is an integrated diagnostic approach for prevention of CVDs by monitoring the heart conditions.

According to the data by World Health Organization, more than 17.9 million people worldwide, die of Cardiovascular diseases (CVDs), every year. This scenario consequently escalates the demand for advanced healthcare facilities that offer precise diagnostics, monitoring and treatments options for patients suffering from CVDs, thereby propagating the growth of global cardiac biomarkers market. However, limited use of biomarkers test in specific cases, and risk of skeletal injury are the limiting factors expected to slow down the growth of cardiac biomarkers market.

The global cardiac biomarkers market share has been analyzed based on type, application, location of testing and geography. Based on product type, the cardiac biomarkers market is segmented into myocardial muscle creatine kinase (CK-MB), myoglobin, brain natriuretic peptide (BNPs), troponins (T and I), or NT-proBNP, ischemia modified albumin (IMA), and others. Based on application, the market is categorized into myocardial infarction, congestive heart failure, acute coronary syndrome, atherosclerosis, and others. Based on location of testing, the market is divided into point of care testing and laboratory testing. Geographic breakdown and analysis of each of the previously mentioned segments include regions comprising North America, Europe, Asia-Pacific, and RoW.

Companies Mentioned

A selection of companies mentioned in this report includes:

  • Roche Diagnostics
  • Siemens Healthcare
  • Abbott Laboratories
  • Alere Inc.
  • Bio-Rad Laboratories
  • Becton, Dickinson and Company
  • BioMerieux
  • Beckman Coulter
  • Randox laboratories
  • Thermo Fisher Scientific